E. J. CHEADLE ET AL: "Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 4, 20 January 2010 (2010-01-20), pages 1885 - 1896, XP055034825, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0901440 (B1)

M. HUDECEK ET AL: "The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor", BLOOD, vol. 116, no. 22, 25 November 2010 (2010-11-25), pages 4532 - 4541, XP055034816, ISSN: 0006-4971, DOI: 10.1182/blood-2010-05-283309 (B1)

WO-A2-02/077029 (B1)

TILL BRIAN G ET AL: "Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells", BLOOD, vol. 112, no. 6, September 2008 (2008-09-01), pages 2261 - 2271, XP002718371, ISSN: 0006-4971 (B1)

WO-A1-2012/129514 (B1)

PHILIPP KOEHLER ET AL: "Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia", ADVANCES IN HEMATOLOGY, vol. 180, no. 9, 1 January 2012 (2012-01-01), pages 6365 - 13, XP055094721, ISSN: 1687-9104, DOI: 10.1073/pnas.0710198105 (B1)